Related references
Note: Only part of the references are listed.The enigmatic membrane fatty acid transporter CD36: New insights into fatty acid binding and their effects on uptake of oxidized LDL
Anthony G. Jay et al.
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS (2018)
Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol
Nabil G. Seidah
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol
Nabil G. Seidah
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2017)
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Marc S. Sabatine et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Prognostic value of PCSK9 levels in patients with acute coronary syndromes
Baris Gencer et al.
EUROPEAN HEART JOURNAL (2016)
Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events
Paul M. Ridker et al.
EUROPEAN HEART JOURNAL (2016)
PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study
Jin M. Cheng et al.
ATHEROSCLEROSIS (2016)
Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis
Charalambos Vlachopoulos et al.
ATHEROSCLEROSIS (2016)
Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering
Giuseppe Danilo Norata et al.
CARDIOVASCULAR RESEARCH (2016)
Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors
Karin Leander et al.
CIRCULATION (2016)
Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015)
Sandy Elbitar et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2016)
PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFR
Kyrill S. Rogacev et al.
PLOS ONE (2016)
Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders
Daiana Ibarretxe et al.
CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS (2016)
Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9
Ji Miao et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention
Yiming M. Zhu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk
Montse Guardiola et al.
CLINICAL SCIENCE (2015)
Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials
A. Sahebkar et al.
DIABETES OBESITY & METABOLISM (2015)
Removal of Plasma Mature and Furin-Cleaved Proprotein Convertase Subtilisin/Kexin 9 by Low-Density Lipoprotein-Apheresis in Familial Hypercholesterolemia: Development and Application of a New Assay for PCSK9
Mika Hori et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Proprotein Convertase Subtilisin/Kexin type 9, C-Reactive Protein, Coronary Severity, and Outcomes in Patients With Stable Coronary Artery Disease A Prospective Observational Cohort Study
Jian-Jun Li et al.
MEDICINE (2015)
Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
Sungsoon Fang et al.
NATURE MEDICINE (2015)
Predicting Cardiovascular Risk in Type 2 Diabetes: the Heterogeneity Challenges
M. Odette Gore et al.
CURRENT CARDIOLOGY REPORTS (2015)
Epigenetic Changes in Bone Marrow Progenitor Cells Influence the Inflammatory Phenotype and Alter Wound Healing in Type 2 Diabetes
Katherine A. Gallagher et al.
DIABETES (2015)
LDL Receptor-Related Protein-1 (LRP1) Regulates Cholesterol Accumulation in Macrophages
Anna P. Lillis et al.
PLOS ONE (2015)
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
Gregory G. Schwartz et al.
AMERICAN HEART JOURNAL (2014)
Having excess levels of PCSK9 is not sufficient to induce complex formation between PCSK9 and the LDL receptor
Catherine J. Wooten et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2014)
Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease
Sha Li et al.
ATHEROSCLEROSIS (2014)
Circulating Levels of Proprotein Convertase Subtilisin Kexin Type 9 are Elevated by Fibrate Therapy A Systematic Review and Meta-Analysis of Clinical Trials
Amirhossein Sahebkar
CARDIOLOGY IN REVIEW (2014)
Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease
Yan Zhang et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2014)
Isolation and characterization of the circulating truncated form of PCSK9
Bomie Han et al.
JOURNAL OF LIPID RESEARCH (2014)
PCSK9 is a critical regulator of the innate immune response and septic shock outcome
Keith R. Walley et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment
Christian Werner et al.
VASCULAR PHARMACOLOGY (2014)
Executive Summary: Heart Disease and Stroke Statistics-2013 Update A Report From the American Heart Association
Alan S. Go et al.
CIRCULATION (2013)
Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis
Hagai Tavori et al.
CIRCULATION RESEARCH (2013)
Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
Tanja Kosenko et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Effect of anticoagulants on multiplexed measurement of cytokine/chemokines in healthy subjects
Angelique Biancotto et al.
CYTOKINE (2012)
Bio-Rad'sBio-Plex® suspension array system, xMAP technology overview
Brett Houser
ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY (2012)
In Vivo Evidence That Furin from Hepatocytes Inactivates PCSK9
Rachid Essalmani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Beyond LDL Cholesterol, a New Role for PCSK9
Omar N. Akram et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Genetic and Metabolic Determinants of Plasma PCSK9 Levels
Susan G. Lakoski et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Validity of multiplex-based assays for cytokine measurements in serum and plasma from non-diseased subjects: Comparison with ELISA
Laure Dossus et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2009)
Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects -: Results from the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Raimpril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) studies
Samy Hadjadj et al.
DIABETES CARE (2008)
Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma
Masatoshi Jinnin et al.
NATURE MEDICINE (2008)
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Antoine E. Karnoub et al.
NATURE (2007)
Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c
P Costet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Simultaneous measurement of 25 inflammatory markers and neurotrophins in neonatal dried blood spots by immunoassay with xMAP technology
K Skogstrand et al.
CLINICAL CHEMISTRY (2005)
Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum
CA Ray et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2005)
Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin:: randomised, double blind, placebo controlled trial (the DIABHYCAR study)
M Marre et al.
BRITISH MEDICAL JOURNAL (2004)
Overall C as a measure of discrimination in survival analysis:: model specific population value and confidence interval estimation
MJ Pencina et al.
STATISTICS IN MEDICINE (2004)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus - A meta-analysis
AM Kanaya et al.
ARCHIVES OF INTERNAL MEDICINE (2002)
The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and Ramipril (DIABHYCAR) study:: Design, organization, and patient recruitment
M Lièvre et al.
CONTROLLED CLINICAL TRIALS (2000)
Share Paper
